Phase 4 N=141 Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting
Post-operative Nausea and Vomiting
Primary: Nausea Scale — 3.5; 4.0; 4.0; 2.0 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=23 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Progression-Free Survival (PFS) — 6.05; 5.26 months — p=0.058
N/A N=94 Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
Stage 0 Breast Cancer · Stage I Breast Cancer · Stage IA Breast Cancer
Primary: Contralateral Prophylactic Mastectomy (CPM) Knowledge Assessed by Surveys for CPM-DA Participants vs. UC Participants — 62.47; 51.33 score on a scale
N/A N=921 Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)
Gestational Diabetes · Pregnancy · Glucose Intolerance
Primary: Large for Gestational Age (LGA) Infant — 34; 35; 28; 34 Participants — p=0.668
N/A N=116 AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcer
Primary: The Number of Participants Meeting Criteria of Complete Wound Closure, as Assessed by the Investigator at or Before Week 12 of the Treatment Phase, Which is Confirmed…
Phase 2 N=20 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 29.5; 25.1 MEq/min — p=0.8
Early Phase 1 N=103 Leptin Infusion and Endothelial Vasomotor Response
Endothelial Dysfunction · Obesity · Vasodilation
Primary: Forearm Blood-flow (FBF) — 1.75; 3.1; NA; NA ml/100 mg tissue/min
N/A N=63 Combination of SBRT With Sequential S-1 for Treating Locally Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: One-year Overall Survival Rate — 46 Participants
Phase 2 N=49 Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy
Lung Cancer
Primary: AUC Value Symptom Severity Differences — 31.18; 44.98; 17.13; 26.64 Units on a scale *week
Phase 2 N=34 Restoring Cognitive Control (ReCon) in Acute Nicotine Withdrawal
Impulse Control Disorders
Primary: Safety and Tolerability of SXC-2023. — 0; 0; 0; 0 Events
Phase 2 N=24 Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Overall Survival — 19.1 months
N/A N=419 MedStar Health Type 2 Diabetes Pathway to Control
Type 2 Diabetes Mellitus · Hyperglycemia
Primary: Percentage Change in Hemoglobin A1C From Baseline to 3 Months — 3.08; 1.64 percentage — p=0.05
N/A N=82 IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Postero-anterior Spine Bone Mineral Density by DXA — 0.891; 0.887; 0.874 g/cm2 — p=0.03
Phase 4 N=220 The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity
Rotavirus Infection · Vaccine Response Impaired · Vaccine Virus Shedding
Primary: Number (or Percentage) of Infants in Each Study Arm Who Test Positive for Fecal Rotavirus Vaccine-strain Virus Shedding Post-vaccination — 63; 55 Participants
Phase 2 N=65 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Pancreatic Neoplasms · Pancreatic Cancer · Cancer of Pancreas
Primary: Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug — 0; 0; 0; 1 Adverse events